Advertisement
Advertisement

ACAD

ACAD logo

Acadia Pharmaceuticals Inc.

21.32
USD
Sponsored
+0.37
+1.77%
May 21, 16:00 UTC -4
Closed
exchange

After-Market

21.32

0.00
+0.02%

Acadia Pharmaceuticals Inc. Profile

About

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company suffered a setback when the FDA issued a complete response letter to the supplemental new drug application for Nuplazid for treating dementia-related psychosis. Acadia resubmitted the supplemental new drug application to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis. Notably, several additional studies on Nuplazid n targeting different CNS indications, such as?dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and as an adjunctive treatment of major depressive disorder (MDD) are currently underway.

Info & Links

CEO

Catherine Owen Adams

Headquarters

12830 El Camino Real,Suite 400
SAN DIEGO, CA 92130, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

https://www.acadia.com/

Auditor

Ernst & Young LLP

Share holders

29

Employees

798

Acadia Pharmaceuticals Inc. Statistics

Valuation Measures

Market Capitalization2

3.65B

Enterprise Value

3.37B

Enterprise Value/EBITDA(ttm)

37.88

Price to Earnings Ratio(ttm)

32.71

Price to Sales(ttm)

3.59

Price to Book(mrq)

3.11

Price to Cash(ytd)

25.44

Profitability

Gross Margin(ttm)

91.70%

Operating Margin(ttm)

10.88%

Profit Margin(ttm)

34.99%

Return on Equity(ttm)

12.49%

Return on Invested Capital(ttm)

35.84%

Return on Assets(ttm)

8.88%

Income Statement

Revenue(ttm)

1.10B

Revenue Per Share(ttm)

6.40

Gross Profit(ttm)

1.00B

EBITDA(ttm)3

88.95M

Net Income Available to Common(ttm)

375.65M

Diluted EPS(ttm)

2.29

Share Statistics

Beta (5Y Monthly)

0.83

52-Week Change

-1.71%

S&P 500 52-Week Change

27.39%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

171.24M

Dividend Yield

0.00%

Float4

125.31M

% Held by Insiders

26.50%

% Held by Institutions

96.71%

Balance Sheet

Total Cash(mrq)

851.46M

Total Cash Per Share(mrq)

4.97

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

3.83%

Quick Ratio(mrq)

3.71%

Book Value Per Share(mrq)

7.21

Cash Flow

Operating Cash Flow Per Share(ytd)

0.65

Free Cash Flow(ytd)

105.15M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement